[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521874":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":35,"locations":44,"responsibleParty":148,"collaborators":150,"id":154,"slug":34,"hasResults":155,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":155,"sex":161,"minAge":162,"maxAge":34,"enrollmentInfo":163,"targetDuration":34,"studyType":166,"phases":167,"briefSummary":169,"conditions":170,"keywords":184,"overallStatus":47,"whyStopped":34,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":203},{"fullName":5,"class":6},"Frantz Viral Therapeutics, LLC","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Artesunate ointment","ACTIVE_COMPARATOR","Artesunate formulated as topical ointment, 40% Four 5-day cycles of artesunate ointment every 2 weeks",[13],"Drug: Artesunate ointment",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo ointment","PLACEBO_COMPARATOR","Placebo ointment Four 5-day cycles of placebo ointment every 2 weeks",[19],"Drug: Placebo ointment",[21,29],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","topical ointment, as a non-surgical treatment",[9],[26,27,28],"Artesunic acid","Dihydroartemisinin (DHA)","Artemisinin",{"type":22,"name":15,"description":30,"armGroupLabels":31,"otherNames":32},"topical placebo ointment",[15],[33],"Placebo to artesunate ointment",null,[36,41],{"name":37,"role":38,"phone":39,"phoneExt":34,"email":40},"Mihaela Plesa","CONTACT","440-255-1155","fvtinfo@frantzgroup.com",{"name":42,"role":38,"phone":43,"phoneExt":34,"email":34},"Ahmad Bayat, MD","301-956-2523",[45,63,79,108,130],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Florida Gynecologic Oncology","RECRUITING","Fort Myers","Florida","33905","United States",{"type":53,"coordinates":54},"Point",[55,56],-81.84059,26.62168,{"lat":56,"lon":55},[59],{"name":60,"role":38,"phone":61,"phoneExt":34,"email":62},"Edward C. Grendys, MD FACOG, FACS","239-334-6626","Edward.Grendys@usa.genesiscare.com",{"facility":64,"status":47,"city":65,"state":66,"zip":67,"country":51,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Ascension St. Vincent","Indianapolis","Indiana","46260",{"type":53,"coordinates":69},[70,71],-86.15804,39.76838,{"lat":71,"lon":70},[74,77],{"name":75,"role":38,"phone":34,"phoneExt":34,"email":76},"Sarah Goodrich, MD","inindgynoncresearch@ascension.org",{"name":75,"role":78,"phone":34,"phoneExt":34,"email":34},"PRINCIPAL_INVESTIGATOR",{"facility":80,"status":47,"city":81,"state":82,"zip":83,"country":51,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Cleveland Clinic Fairview Hospital","Cleveland","Ohio","44111",{"type":53,"coordinates":85},[86,87],-81.69541,41.4995,{"lat":87,"lon":86},[90,94,97,99,102,104,106],{"name":91,"role":38,"phone":92,"phoneExt":34,"email":93},"Donna White","216-445-8090","whited11@ccf.org",{"name":95,"role":38,"phone":92,"phoneExt":34,"email":96},"Megan Park","parkm2@ccf.org",{"name":98,"role":78,"phone":34,"phoneExt":34,"email":34},"Chad Michener, MD",{"name":100,"role":101,"phone":34,"phoneExt":34,"email":34},"Mariam AlHilli, MD","SUB_INVESTIGATOR",{"name":103,"role":101,"phone":34,"phoneExt":34,"email":34},"Steven Waggonner, MD",{"name":105,"role":101,"phone":34,"phoneExt":34,"email":34},"Robert DeBernardo, MD",{"name":107,"role":101,"phone":34,"phoneExt":34,"email":34},"Roberto Vargas, MD",{"facility":109,"status":47,"city":81,"state":82,"zip":110,"country":51,"cosmosGeoPoint":111,"geoPoint":113,"contacts":114},"Cleveland Clinic Foundation","44195",{"type":53,"coordinates":112},[86,87],{"lat":87,"lon":86},[115,116,117,118,120,121,122,123,124,126,128],{"name":91,"role":38,"phone":92,"phoneExt":34,"email":93},{"name":95,"role":38,"phone":92,"phoneExt":34,"email":96},{"name":98,"role":78,"phone":34,"phoneExt":34,"email":34},{"name":119,"role":101,"phone":34,"phoneExt":34,"email":34},"Lindsey Beffa, MD",{"name":103,"role":101,"phone":34,"phoneExt":34,"email":34},{"name":105,"role":101,"phone":34,"phoneExt":34,"email":34},{"name":107,"role":101,"phone":34,"phoneExt":34,"email":34},{"name":100,"role":101,"phone":34,"phoneExt":34,"email":34},{"name":125,"role":101,"phone":34,"phoneExt":34,"email":34},"Johanna Kelley, MD",{"name":127,"role":101,"phone":34,"phoneExt":34,"email":34},"Daniel Margul, MD",{"name":129,"role":101,"phone":34,"phoneExt":34,"email":34},"Michelle Kuznicki, MD",{"facility":131,"status":47,"city":132,"state":82,"zip":133,"country":51,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"Hillcrest Hospital","Mayfield Heights","44124",{"type":53,"coordinates":135},[136,137],-81.4579,41.51922,{"lat":137,"lon":136},[140,141,142,143,144,145,146,147],{"name":91,"role":38,"phone":92,"phoneExt":34,"email":93},{"name":95,"role":38,"phone":92,"phoneExt":34,"email":96},{"name":98,"role":78,"phone":34,"phoneExt":34,"email":34},{"name":100,"role":101,"phone":34,"phoneExt":34,"email":34},{"name":103,"role":101,"phone":34,"phoneExt":34,"email":34},{"name":105,"role":101,"phone":34,"phoneExt":34,"email":34},{"name":107,"role":101,"phone":34,"phoneExt":34,"email":34},{"name":119,"role":101,"phone":34,"phoneExt":34,"email":34},{"type":149,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR",[151],{"name":152,"class":153},"The Cleveland Clinic","OTHER","100521874",false,"NCT06075264","Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2\u002F3)","A Phase II Double-blind, Placebo-controlled, Randomized Trial of Topical Artesunate Ointment for the Treatment of Patients With Vulvar High-grade Squamous Intraepithelial Lesions (Vulvar HSIL)","ART-VIN IIB","Inclusion Criteria:\n\n* Adult women age ≥ 18 years\n* Capable of informed consent\n* Able to collaborate with planned follow-up (transportation, compliance history, etc)\n* Biopsy diagnosis of high-grade vulvar dysplasia (VIN2, VIN3, VIN2\u002F3, HSIL), including both new and recurrent disease. A biopsy diagnosis of vulvar high-grade squamous intraepithelial lesion within the previous 3 months which was not excised or otherwise treated may be accepted for study entry.\n* Positive HPV test at study entry (any genotype).\n* Women of childbearing potential agree to use birth control during the dosing phase (through week 8).\n* Laboratory values at Screening of:\n\n  * Serum alanine transaminase (SGPT\u002FALT) \\\u003C 5 x upper limit of normal (ULN)\n  * Serum aspartate transaminase (SGOT\u002FAST) \\\u003C 5 x ULN\n  * Serum Bilirubin (total) \\\u003C 2.5 x ULN\n  * Serum Creatinine ≤ 1.5 x ULN\n* Weight ≥ 50kg\n\nExclusion Criteria:\n\n* Pregnant and nursing women\n* Concurrent anal, vulvar, or cervical cancer\n* HIV-positive participants with a CD4 count \\\u003C 200\n* Participants infected with HIV-1 if not on a stable, suppressive antiretroviral therapy (ART) regimen.\n* Unwillingness to undergo an excisional procedure at week 18 to either remove HSIL lesions, or to document histologic regression at a site where HSIL was present at study entry.\n* Currently receiving systemic chemotherapy or radiation therapy for another cancer.\n* Concomitant use of Efavirenz for HIV antiretroviral treatment\n* Concomitant use of strong UGT inhibitors\n* Concomitant use of imiquimod, cidofovir, or 5-fluorouracil (5-FU) for the duration of the study\n* Concurrent dermatological conditions affecting the vulva (e.g., herpetic lesion, Crohn's disease, hidradenitis suppurativa) or vulvar dermatoses (e.g., lichen sclerosis or planus, atopic dermatitis, genital atrophy).\n* Concurrent treatment with systemic corticosteroids","FEMALE","18 Years",{"count":164,"type":165},27,"ESTIMATED","INTERVENTIONAL",[168],"PHASE2","This is a phase II double-blind, placebo-controlled study of artesunate ointment for the treatment of HPV-associated vulvar HSIL (usual type vulvar intraepithelial neoplasia 2\u002F3).",[171,172,173,174,175,176,177,178,179,180,181,182,183],"Vulvar Diseases","HPV Infection","Vulvar HSIL","Pre-Cancerous Dysplasia","HPV Disease","VIN, Usual Type","VIN 2 of Usual Type","VIN 3 of Usual Type","Vin II","Vin III","VIN Grade 2","VIN Grade 3","High Grade Intraepithelial Neoplasia",[185,186,187,188,189,190,191,192,193],"topical treatment","ointment","non-surgical","vulvar cancer prevention","high-risk HPV","human papillomavirus","HPV","vulvar HSIL","High grade lesions","2025-08-13",{"date":196,"type":197},"2025-08-14","ACTUAL",{"date":199,"type":197},"2023-12-06",{"date":201,"type":165},"2027-12",{"name":5,"class":6},5]